Patient baseline characteristics

Characteristics1 L (n = 62)2 L (n = 20)
Age, n (%)
  < 65 years37 (59.7)7 (35.0)
  ≥ 65 years25 (40.3)13 (65.0)
Median age (range), years62 (36–85)69 (30–80)
Sex, n (%)
 Male43 (69.4)15 (75.0)
 Female19 (30.6)5 (25.0)
ECOG PS, n (%)
 037 (59.7)9 (45.0)
 125 (40.3)11 (55.0)
MSKCC prognostic risk group, n (%)
 Favorable2 (3.2)0
 Intermediate53 (85.5)17 (85.0)
 Poor7 (11.3)3 (15.0)
IMDC prognostic risk group, n (%)
 Favorable24 (38.7)5 (25.0)
 Intermediate27 (43.5)13 (65.0)
 Poor11 (17.7)2 (10.0)
Median time since diagnosis of metastatic disease (range), months2.5 (0.4–90.4)15.0 (1.6–80.4)
Number of prior anticancer therapy lines for metastatic or locally advanced disease, n (%)
 062 (100.0)a0
 1019 (95.0)
 200
 300
  ≥ 401 (5.0)
PD-L1 status (≥ 1% tumor cells), n (%)
 Positive20 (32.3)4 (20.0)
 Negative21 (33.9)9 (45.0)
 Not evaluable21 (33.9)7 (35.0)

a One patient (1.6%) received prior adjuvant therapy

1 L first-line subgroup, 2 L second-line subgroup, ECOG PS Eastern Cooperative Oncology Group performance status, MSKCC Memorial Sloan-Kettering Cancer Center, IMDC International Metastatic Renal Cell Carcinoma Database Consortium, PD-L1 programmed death-ligand 1